Introduction
============

Breast cancer is one of the main causes of cancer deaths in women,[@b1-ott-9-2153] which was responsible for 23% of total cancer cases and 14% of cancer deaths.[@b2-ott-9-2153] With the improvements in early detection and treatment, the number of cancer survivors continued to increase, in which women with breast cancer accounted for 22% of total cancer survivors in 2012.[@b3-ott-9-2153] However, the problems related to breast cancer and cancer treatment, such as cardiac toxicity of adjuvant systemic therapy,[@b4-ott-9-2153],[@b5-ott-9-2153] arm or shoulder problems, body image,[@b6-ott-9-2153] change in social life, fear,[@b7-ott-9-2153] and poorer quality of life[@b8-ott-9-2153] were negatively associated with the overall well-being of breast cancer survivors.

A growing body of evidence indicated that exercise intervention results in beneficial outcomes in cancer patients. Some studies had suggested that exercise increased cardiorespiratory fitness,[@b9-ott-9-2153] physical performance,[@b10-ott-9-2153] and reduced overall mortality.[@b11-ott-9-2153] There were also studies demonstrating that exercise was associated with improvements in the symptom of depression,[@b12-ott-9-2153] body image, self-esteem,[@b13-ott-9-2153] and quality of life,[@b14-ott-9-2153]--[@b16-ott-9-2153] though some conclusions were not inconsistent in terms of fatigue.[@b17-ott-9-2153]

Previously, these effects of exercise intervention in breast cancer patients had been assessed in several meta-analyses and systematic reviews.[@b18-ott-9-2153]--[@b22-ott-9-2153] However, some of them only summarized some of effects related to intervention,[@b18-ott-9-2153],[@b19-ott-9-2153] or compared the effects of group exercise with individual exercise.[@b20-ott-9-2153] Others either only focused on one special symptom,[@b21-ott-9-2153] or evaluated the efficacy of Tai Chi Chuan alone.[@b22-ott-9-2153] Moreover, new evidences in recent years have not been included. Thus, we aim to comprehensively summarize the effects of exercise intervention on breast cancer patients based on the available data from randomized controlled trials.

Methods
=======

Literature search
-----------------

We searched PubMed, Elsevier, and Google Scholar up to March 2015. The reference lists of relevant systematic reviews and meta-analyses were also examined to identify additional studies. The search terms used in this meta-analysis were related to breast cancer (breast neoplasm, cancer, tumour, tumor, carcinoma) and exercise (exercise, physical activity, sport, weight training).

Inclusion criteria
------------------

Studies were considered eligible if they met the following criteria: 1) were written in English; 2) adopted a randomized controlled trial design, comparing exercise intervention group with control group (usual care, maintain current activity level, or waitlist); 3) included adults diagnosed with breast cancer; and 4) evaluated the effects of exercise in breast cancer patients.

Studies were excluded if: 1) included mixed cancer populations, including other types of cancer patients; 2) included other types of intervention (exercise intervention combined with diet); and 3) exercise merely focused on upper limb or arm.

Data extraction
---------------

Relevant data were independently extracted by GQ Zhu and X Zhang with a standard excel template, including 1) characteristics of the study and participants (first author, year of publication, mean age, sample size); 2) content of exercise intervention: exercise type, timing (before, during, or after treatment), and the frequency, intensity, and duration of intervention; 3) outcomes of intervention (quality of life, depression, anxiety, fatigue, muscle strength, body composition, physiological markers); and 4) assessment methods. Any disagreements were checked and discussed until a consensus was reached.

Methodological quality assessment
---------------------------------

The methodological quality of the studies were independently assessed by two reviewers (GQ Zhu and YL Wang) using the Delphi criteria list,[@b23-ott-9-2153] which is a set of nine criteria for quality assessment of randomized controlled trials. It was hard to blind the participants and providers in the interventional study. Therefore, participants blinding and provider blinding were not rated, and we only assessed the blinding of the outcome assessors. Each item was scored as yes (+) or no (−).

Statistical analysis
--------------------

The outcomes were assessed if the data were available in at least two studies. For continuous outcomes, standardized mean differences with 95% confidence intervals (CIs) were calculated, with *P*\<0.05 considered statistically significant. Statistical heterogeneity among studies was measured by *I*^2^ test, in which values above 25% and 50% were considered as the indicative of moderate and high heterogeneity, respectively.[@b24-ott-9-2153] A fixed-effect model was adopted when *I*^2^\<50%; otherwise, a random-effect model was used.

In the presence of heterogeneity, subgroup analysis was performed based on the measurement methods or the type of exercise. Besides, sensitivity analysis was carried out to evaluate the influence of a single study to the overall estimate. Publication bias was estimated through Begg's test and Egger's linear regression, with *P*\<0.10 consumed as an indication of publication bias.[@b25-ott-9-2153] All analyses were conducted using Review Manager Version 5.3 (Cochrane Collaboration, Copenhagen, Denmark) and Stata 12.0 (College Station, TX, USA).

Results
=======

Study selection
---------------

A total of 3,429 records were identified from the database ([Figure 1](#f1-ott-9-2153){ref-type="fig"}). After screening the titles and abstracts, the full texts of 161 articles were further reviewed for eligibility. Finally, 33 articles[@b26-ott-9-2153]--[@b58-ott-9-2153] were included and assessed for methodological quality, with 128 articles excluded in which the aim, intervention type, or design of the study failed to meet the inclusion criteria.

Characteristics of the exercise interventions
---------------------------------------------

There were 2,659 breast cancer patients, with the mean age of 54 (46.3--60.6) years ([Table 1](#t1-ott-9-2153){ref-type="table"}). The main types of exercise interventions reported in this meta-analysis were aerobic, resistance, and stretching exercises. Besides, there were also six studies on yoga intervention,[@b28-ott-9-2153],[@b39-ott-9-2153],[@b42-ott-9-2153],[@b4-ott-9-2153],[@b50-ott-9-2153],[@b52-ott-9-2153] two studies on tai chi chuan,[@b35-ott-9-2153],[@b55-ott-9-2153] and one on dancing.[@b46-ott-9-2153] Twenty Five studies performed intervention after treatment,[@b26-ott-9-2153],[@b28-ott-9-2153],[@b29-ott-9-2153],[@b31-ott-9-2153],[@b33-ott-9-2153]--[@b36-ott-9-2153],[@b38-ott-9-2153],[@b40-ott-9-2153],[@b41-ott-9-2153],[@b44-ott-9-2153],[@b46-ott-9-2153]--[@b58-ott-9-2153] seven studies during treatment,[@b20-ott-9-2153],[@b27-ott-9-2153],[@b32-ott-9-2153],[@b37-ott-9-2153],[@b43-ott-9-2153],[@b45-ott-9-2153],[@b51-ott-9-2153] and the remaining two studies before treatment.[@b39-ott-9-2153],[@b42-ott-9-2153] The duration of intervention lasted from 6 weeks to 12 months, with the frequency of intervention varying from two times a week to every day. The intensity of exercise also varied from low to vigorous in different situations, among which the moderate intensity was most frequently reported.

Methodological quality of included studies
------------------------------------------

We assessed 33 articles according to the Delphi criteria list, and seven criteria were examined in each of the study. In all, 14 studies met five criteria,^26,30,35,38--41,51--54,56--58\ 12^ studies more than five criteria,[@b29-ott-9-2153],[@b31-ott-9-2153],[@b33-ott-9-2153],[@b34-ott-9-2153],[@b36-ott-9-2153],[@b37-ott-9-2153],[@b42-ott-9-2153],[@b44-ott-9-2153],[@b46-ott-9-2153],[@b48-ott-9-2153]--[@b50-ott-9-2153] and the remaining 7 studies less than five criteria.[@b27-ott-9-2153],[@b28-ott-9-2153],[@b32-ott-9-2153],[@b43-ott-9-2153],[@b45-ott-9-2153],[@b47-ott-9-2153],[@b55-ott-9-2153] Of these, 19 studies failed to conceal the allocation,[@b26-ott-9-2153]--[@b28-ott-9-2153],[@b32-ott-9-2153]--[@b34-ott-9-2153],[@b38-ott-9-2153]--[@b40-ott-9-2153],[@b43-ott-9-2153],[@b45-ott-9-2153],[@b47-ott-9-2153],[@b52-ott-9-2153]--[@b58-ott-9-2153] and 22 studies did not blind the outcome assessor.[@b27-ott-9-2153]--[@b28-ott-9-2153],[@b30-ott-9-2153]--[@b32-ott-9-2153],[@b35-ott-9-2153]--[@b36-ott-9-2153], [@b38-ott-9-2153]--[@b41-ott-9-2153],[@b43-ott-9-2153],[@b45-ott-9-2153]--[@b47-ott-9-2153],[@b51-ott-9-2153]--[@b55-ott-9-2153],[@b57-ott-9-2153],[@b58-ott-9-2153] Besides, 14 studies were not intention-to-treat analysis ([Table 2](#t2-ott-9-2153){ref-type="table"}).[@b26-ott-9-2153]--[@b28-ott-9-2153],[@b30-ott-9-2153],[@b32-ott-9-2153],[@b35-ott-9-2153],[@b37-ott-9-2153],[@b41-ott-9-2153],[@b43-ott-9-2153],[@b45-ott-9-2153],[@b47-ott-9-2153],[@b49-ott-9-2153],[@b55-ott-9-2153],[@b56-ott-9-2153]

Pooled effect estimates for outcome measures
--------------------------------------------

In this meta-analysis, we examined the effects of exercise intervention on quality of life, psychological outcomes, body composition, physical function and symptom, and physiological markers of breast cancer survivors. A total of 53 outcomes were evaluated, which were reported in at least two studies ([Table 3](#t3-ott-9-2153){ref-type="table"}).

Results of quality of life
--------------------------

The quality of life was reported as an outcome in 18 studies,[@b26-ott-9-2153],[@b30-ott-9-2153],[@b31-ott-9-2153],[@b36-ott-9-2153],[@b37-ott-9-2153],[@b41-ott-9-2153],[@b42-ott-9-2153],[@b45-ott-9-2153],[@b46-ott-9-2153],[@b51-ott-9-2153]--[@b58-ott-9-2153] among which 10 studies used the Functional Assessment of Cancer Therapy-Breast (FACT-B) and the Functional Assessment of Cancer Therapy--General (FACT-G) questionnaire,[@b31-ott-9-2153],[@b36-ott-9-2153],[@b37-ott-9-2153],[@b41-ott-9-2153],[@b45-ott-9-2153],[@b46-ott-9-2153],[@b51-ott-9-2153],[@b53-ott-9-2153]--[@b55-ott-9-2153] 4 studies the Medical Outcomes Study Short Form health survey (SF-36) questionnaire,[@b26-ott-9-2153],[@b46-ott-9-2153],[@b51-ott-9-2153],[@b57-ott-9-2153] and two studies Treatment of Cancer-Quality of Life questionnaire (EORTCQoLC30).[@b42-ott-9-2153],[@b58-ott-9-2153] The other 4 studies used SF-12 health survey (SF-12),[@b52-ott-9-2153] the Functional Assessment of Cancer Therapy--Anemia,[@b30-ott-9-2153] the World Health Organization Quality of Life (WHOQOL-BREF),[@b45-ott-9-2153] and the Cancer Rehabilitation Evaluation System-Short Form,[@b56-ott-9-2153] respectively. We only pooled the outcomes that data could be extracted in at least two studies. Therefore, the data of 12 studies, involving 15 quality life domains, were included in this meta-analysis.[@b26-ott-9-2153],[@b31-ott-9-2153],[@b36-ott-9-2153],[@b37-ott-9-2153],[@b41-ott-9-2153],[@b45-ott-9-2153],[@b46-ott-9-2153],[@b51-ott-9-2153],[@b53-ott-9-2153]--[@b55-ott-9-2153],[@b57-ott-9-2153]

Measured by SF-36 or MOS SF-36, the exercise intervention significantly improved the mental health (*I*^2^=0%, *P*=0.006, 95% CI: 0.11, 0.62, [Figure 2](#f2-ott-9-2153){ref-type="fig"}) and general health (*I*^2^=95%, *P*=0.02, 95% CI: 0.70, 8.48, [Figure 2](#f2-ott-9-2153){ref-type="fig"}) compared with the control groups. Besides, exercise was associated with a significant increase in emotion well-being (*I*^2^=2%, *P*=0.0006, 95% CI: 0.12, 0.43, [Figure 2](#f2-ott-9-2153){ref-type="fig"}) and social well-being subscales (*I*^2^=0%, *P*=0.01, 95% CI: 0.19, 1.69, [Figure 2](#f2-ott-9-2153){ref-type="fig"}) of the Functional Assessment of Cancer Therapy. The pooled results of five studies showed a significant increase in breast cancer subscale of the Functional Assessment of Cancer Therapy from exercise (*I*^2^=15%, *P*=0.000001, 95% CI: 1.85, 4.04) ([Table 3](#t3-ott-9-2153){ref-type="table"}).[@b36-ott-9-2153],[@b37-ott-9-2153],[@b44-ott-9-2153],[@b54-ott-9-2153],[@b57-ott-9-2153]

However, substantial heterogeneity was observed for some outcomes. There was no evidence of publication bias except for SF-36 role-emotion (*P*=0.062, [Table 3](#t3-ott-9-2153){ref-type="table"}).

Results of psychological outcomes
---------------------------------

Pooled data from three studies indicated that the self-esteem score was higher in the intervention group (*I*^2^=0%, *P*=0.02, 95% CI: 0.18, 2.22), measured by the Rosenberg Self-Esteem Scale ([Table 3](#t3-ott-9-2153){ref-type="table"}).[@b29-ott-9-2153],[@b44-ott-9-2153],[@b51-ott-9-2153] Meanwhile, exercise intervention reduced depression (*I*^2^=2%, *P*=0.001, 95% CI: −3.36, −0.80, [Figure 3](#f3-ott-9-2153){ref-type="fig"}) and anxiety score (*I*^2^=0%, *P*\<0.0001, 95% CI: −4.76, −1.58, [Figure 3](#f3-ott-9-2153){ref-type="fig"}), which were of clinical importance. However, the pooled results showed no difference in happiness and stress between intervention and control groups, assessed by the 2-item Fordyce Happiness Measure and the Perceived Stress Scale ([Table 3](#t3-ott-9-2153){ref-type="table"}).

Furthermore, exercise led to improvement in the positive and negative attitudes in breast cancer survivors, measured by the Positive and Negative Affect Schedule (PANAS), of which the PANAS negative score decreased by 3.51 points (*I*^2^=76%, *P*=0.02, 95% CI: −9.92, −0.71) and the PANAS positive score increased by 4.46 points (*I*^2^=0, *P*\<0.00001, 95% CI: 2.48, 6.44) ([Table 3](#t3-ott-9-2153){ref-type="table"}). In addition, measured by the Functional Assessment of Chronic Illness Therapy--Spiritual, exercise was associated with positive effect in spirit compared with control groups (*I*^2^=0%, *P*=0.02, 95% CI: 0.76, 7.13) ([Table 3](#t3-ott-9-2153){ref-type="table"}).

No publication bias were detected in any of the results, except the Pittsburgh Sleep Quality Index (*P*=0.082). High heterogeneity was only found for PANAS negative ([Table 3](#t3-ott-9-2153){ref-type="table"}).

Results of body compositions
----------------------------

Seven parameters were included in this meta--analysis ([Table 3](#t3-ott-9-2153){ref-type="table"}). Body mass index (BMI) was examined in nine studies, and the pooled results indicated it reduced significantly with exercise (*I*^2^=0%, *P*\<0.00001, 95% CI: −1.09, −0.47, [Figure 4](#f4-ott-9-2153){ref-type="fig"}).[@b34-ott-9-2153],[@b35-ott-9-2153],[@b37-ott-9-2153],[@b38-ott-9-2153],[@b40-ott-9-2153],[@b41-ott-9-2153],[@b44-ott-9-2153],[@b49-ott-9-2153],[@b54-ott-9-2153] Besides, the pooled results of four studies showed that exercise was associated with significant increase in lean mass compared with control groups (*I*^2^=57%, *P*=0.04, 95% CI: 0.08, 2.25) ([Table 3](#t3-ott-9-2153){ref-type="table"}).

Similarly, body fat percentage (*I*^2^=57%, *P*=0.02, 95% CI: −3.33, −0.35) and fat mass (*I*^2^=0%, *P*=0.05, 95% CI: −4.83, −0.04) were significantly reduced in the exercise intervention groups ([Table 3](#t3-ott-9-2153){ref-type="table"}). However, there were no significant differences on waist circumference, hip circumference, and waist-to-hip ratio between intervention and control groups.

No publication bias was observed, with only moderate heterogeneity for lean mass and body fat ([Table 3](#t3-ott-9-2153){ref-type="table"}).

Results of physical function and symptom
----------------------------------------

Muscle strength was reported in five studies, which indicated significant improvement (*I*^2^=48%, *P*=0.0009, 95% CI: 1.76, 6.78, [Figure 5](#f5-ott-9-2153){ref-type="fig"}) in exercise intervention group. Besides, no significant improvement was showed on peak oxygen consumption, based on the data from two studies ([Table 3](#t3-ott-9-2153){ref-type="table"}).[@b27-ott-9-2153],[@b30-ott-9-2153],[@b34-ott-9-2153],[@b40-ott-9-2153],[@b41-ott-9-2153]

Fatigue was assessed in 12 studies, the pooled results of which indicated that there was no difference on fatigue between the intervention and control groups ([Figure 6](#f6-ott-9-2153){ref-type="fig"}).[@b29-ott-9-2153],[@b30-ott-9-2153],[@b36-ott-9-2153],[@b37-ott-9-2153],[@b40-ott-9-2153],[@b47-ott-9-2153],[@b50-ott-9-2153],[@b52-ott-9-2153]--[@b54-ott-9-2153],[@b58-ott-9-2153] In the present of high heterogeneity, we performed the subgroup analysis stratified by the measurement method and the type of exercise intervention ([Figure 6](#f6-ott-9-2153){ref-type="fig"}). However, the effect of exercise on the symptom of fatigue still remained insignificant in both of the subgroups, except small reduction in Fatigue Symptom Inventory (*I*^2^=68%, *P*=0.04, 95% CI: −1.68, −0.02). No evidence of publication bias was detected in any of the results ([Table 3](#t3-ott-9-2153){ref-type="table"}).

Results of physiological markers
--------------------------------

Eight physiological markers were examined in this meta-analysis ([Table 3](#t3-ott-9-2153){ref-type="table"}). When the data of postintervention were used, only insulin (*I*^2^=95%, *P*=0.05, 95% CI: −13.64, 0.06) and insulin-like growth factor binding protein (IGFBP)-1 (*I*^2^=46%, *P*\<0.00001, 95% CI: −4.40, −1.91) were signifi-cantly reduced after exercise intervention. However, based on the changed serum concentration of physiological markers after intervention (postintervention minus baseline), exercise significantly reduced the serum concentration of insulin (*I*^2^=97%, *P*\<0.00001, 95% CI: −9.26, −0.33, [Figure 7](#f7-ott-9-2153){ref-type="fig"}), IGFBP-1 (*I*^2^=0%, *P*\<0.00001, 95% CI: −3.93, −1.93, [Figure 7](#f7-ott-9-2153){ref-type="fig"}), and insulin-like growth factor (IGF)-II (*I*^2^=0%, *P*\<0.00001, 95% CI: −61.41, −47.00). Significant increases were shown in interleukin (IL)-6 (*I*^2^=69%, *P*=0.02, 95% CI: 0.27, 2.65) and glucose (*I*^2^=99%, *P*\<0.00001, 95% CI: 0.27, 2.65). There were substantial heterogeneity in some of the physiological markers, and evident publication bias was only observed in IL-6 (*P*=0.046) ([Table 3](#t3-ott-9-2153){ref-type="table"}).

Discussion
==========

In this meta-analysis, we summarized the effects of exercise intervention on breast cancer survivors, including 53 outcomes reported from 33 articles. Results showed that exercise was associated with significant improvements in quality of life, self-esteem, and the response attitude toward life. Besides, it alleviated the symptoms of depression and anxiety in breast cancer survivors. In addition to the beneficial outcome in body composition, exercise also increased muscle strength in the intervention groups. Furthermore, the serum concentration of some physiological markers, such as insulin, IGF-II, and IGFBP-1, was significantly reduced after exercise intervention.

In line with previous meta-analyses,[@b19-ott-9-2153],[@b59-ott-9-2153],[@b60-ott-9-2153] the pooled results supported the evidences that exercise improved the quality of life in cancer patients. However, a significant improvement was shown in general health subscale of SF-36 in our meta-analysis, but not in general health scale of the Functional Assessment of Cancer Therapy.

Similarly, a statistically significant increase was only detected in the social function and emotion function scales of the Functional Assessment of Cancer Therapy, but not in the role emotion and social function subscales of SF-36. It was the same as the evidence of Fong who discovered that exercise improved SF-36 scores in physical function, social function, and mental health with mixed type of cancer survivors.[@b61-ott-9-2153] Thus, despite the fact that exercise was proved to improve quality of life, there were slight differences in the domains of quality life, owing to the differences in the features of patients and exercise, as well as measurement methods.

According to the sensitivity analysis of the Functional Assessment of Cancer Therapy, the study by Mustian was identified as an outlier: the timing of intervention was during treatment in the study by Milne, whereas, the other studies were posttreatment.[@b36-ott-9-2153] When excluding this outliers from analysis, the heterogeneity in the Functional Assessment of Cancer Therapy subscales (social well-being, function well-being, emotion well-being, physical well-being) decreased evidently (*I*^2^=0%, 27%, 20%, 0%, 8%, respectively).

The study by Basen-Engquist was also identified as an outlier, based on the sensitivity analysis of SF-36 subscales: in this study, the exercise intervention was lifestyle intervention, which encouraged participants to integrate activity into daily routine and perform activities they choose.[@b26-ott-9-2153] When this study was excluded, the heterogeneity was evidently decreased in vitality (*I*^2^=0%), body pain of SF-36 (*I*^2^=0%), and general health (*I*^2^=86%).

In our current meta-analysis, we only calculated the effect size of outcomes reported in at least two studies. Therefore, the data of life quality measured by the Functional Assessment of Cancer Therapy--Anemia,[@b30-ott-9-2153] the European Organization for the Research and Treatment of Cancer-Quality of Life (EORTCQoLC30 questionnaire),[@b42-ott-9-2153],[@b58-ott-9-2153] the Cancer Rehabilitation Evaluation System-Short Form,[@b56-ott-9-2153] and the WHOQOL-BREF were not pooled.[@b45-ott-9-2153] Even though all the five studies favored exercise intervention, only three of them reported a clinical significant improvement in quality of life on breast cancer survivors,[@b42-ott-9-2153],[@b45-ott-9-2153],[@b56-ott-9-2153] and the results in other two studies failed to reach statistical significance.[@b30-ott-9-2153],[@b58-ott-9-2153]

We observed a significant improvement in depression, anxiety, and self-esteem in breast cancer patients, which were frequently reported in pervious meta-analyses and systematic reviews with mixed cancer patients.[@b59-ott-9-2153],[@b61-ott-9-2153]--[@b64-ott-9-2153] We also discovered that the attitude toward life in intervention group was more positive than control group. The positive attitude played a critical role in the emotion well-being, which might have some correlation with improved quality of life in breast cancer survivors.

There was no clinical significant change on the symptom of fatigue between groups, based on the pooled results in our meta-analysis, which was consistent with a previous meta-analysis.[@b61-ott-9-2153] However, physical activity was reported to be associated with improvement on the symptom of fatigue in several meta-analyses, both breast and other cancer survivors.[@b19-ott-9-2153],[@b59-ott-9-2153],[@b62-ott-9-2153],[@b65-ott-9-2153],[@b66-ott-9-2153]

In the subgroup analysis based on the measurement methods, a significant decrease of fatigue was only observed in the Fatigue Symptom Inventory. We then stratified the results by the types of intervention, the results of which still remained insignificant. Even yoga, a "mind--body" exercise, had no significant effect on fatigue, which had been suggested to be associated with a moderate reduction of fatigue in a previous study.[@b67-ott-9-2153] We further performed sensitivity analysis, the results of which indicated the studies by Bower and Milne exerted substantial influence to the overall estimate.[@b28-ott-9-2153],[@b36-ott-9-2153] However, when excluding the two studies, the fatigue level was increased in exercise intervention groups (*I*^2^=50%, *P*=0.05, 95% CI: 0.02, 2.19), which had not been reported in previous meta-analysis. Given the current inconsistent conclusions, more researches are needed to further examine this effect.

Several system reviews and meta-analyses had suggested positive effects of exercise on peak oxygen consumption.[@b18-ott-9-2153],[@b19-ott-9-2153],[@b61-ott-9-2153],[@b66-ott-9-2153] However, the pooled results of two studies observed no statistical significance change of peak oxygen consumption between groups, which might be attributed to the small size in our meta-analysis. Furthermore, owing to the lack of sufficient data, the outcomes, such as the 3-minute step test[@b52-ott-9-2153] and the figure-8 running test,[@b38-ott-9-2153] were not included in our meta-analysis, which also showed improvements compared with control groups.

Results indicated that exercise led to a statistically significant reduction in BMI and insulin. Each 5 kg weight gain might increase the breast cancer-specific mortality by 13% and all-caused mortality by 12%.[@b68-ott-9-2153] Besides, research showed that insulin was associated with BMI, and the increase of insulin was related to a twofold increased risk of breast cancer recurrence.[@b69-ott-9-2153] Thus, the decreased BMI and insulin from exercise might potentially contribute to a reduced risk of mortality and recurrence on breast cancer survivors.

Additionally, one study suggested that IGFBP-1 and IGFBP-5 as IGF-I antagonists might block mammary gland development.[@b70-ott-9-2153] However, pooled results showed that IGFBP-1 was significantly decreased in exercise intervention group, while the change of IGF-1 was insignificant. Contrary to previous results, two meta-analyses reported only IGF-I was reduced significantly, and no evidences of significant change were found in insulin, IGFBP-1, and glucose in both breast cancer patients or mixed cancer patients.[@b61-ott-9-2153],[@b62-ott-9-2153] Therefore, given this inconsistency, we should treat the association between exercise and the change of physiological markers with caution, and more researches are needed before making a confirmed conclusion.

The sensitivity analysis of physiological markers identified two outliers: the study by Schmitz and Melinda, in which the duration of intervention lasted for 6 to 12 months, while the durations were 12 to 15 weeks in other studies.[@b34-ott-9-2153],[@b39-ott-9-2153] Therefore, it is likely that the duration of exercise intervention is the source of heterogeneity among these results.

Limitations
-----------

In our meta-analysis, we only included published randomized control trails in two databases, though we further searched the relevant reference lists for potential articles, which may increase the risk of publication bias. Besides, there was a lack of consistency in terms of the outcomes reported and measurement methods among the studies. The outcomes, such as erythrocyte Levels,[@b32-ott-9-2153] salivary cortisol,[@b29-ott-9-2153] were reported in only one study respectively, and we, therefore, failed to calculate their effect sizes in present meta-analysis.

Similarly, the quality of life was measured by different methods, which made it difficult to combine the diverse outcomes. Therefore, we only pooled the outcomes of quality life components measured by the Functional Assessment of Cancer Therapy and SF-36, respectively, which were used in most of the studies.

Furthermore, some data could not be extracted in several studies, and we did not try to contact the authors for detailed information. In addition, we used the mean and standard deviation of postintervention to calculate the effect sizes for most of the data, rather than the changes after the intervention, the results of which may be influenced by the differences at baselines.

Implications for future research and practice
---------------------------------------------

The differences of intervention type, intensity, and duration might account for some variations in the effects of exercise, and we could have performed subgroup analysis based on these differences. However, it would lead to insufficient data to calculate the effect sizes of some outcomes. Therefore, future research should further explore the correlation between intervention effects and the exercise type, intensity, and duration.

Additionally, the survival outcomes in breast cancer survivors are likely to have some correlation with exercise intervention.[@b71-ott-9-2153],[@b72-ott-9-2153] However, the studies included in our current meta-analysis failed to examine this association. Therefore, it is recommended that future studies examine the effects of exercise intervention on survival outcomes and determine whether exercise will provide benefit to the survival outcomes.

Taken together, the present evidences support the idea that exercise intervention is beneficial to breast cancer survivors, although it fails to identify the optimal type, timing, and intensity of exercise intervention. In addition, previous studies demonstrated that it was feasible and safe for various cancer patients to exercise during treatment,[@b73-ott-9-2153] without increasing the risk or exacerbating the symptom of lymphedema.[@b74-ott-9-2153] Nevertheless, some prospective longitudinal studies showed that the physical activity decreased during treatment.[@b75-ott-9-2153],[@b76-ott-9-2153] The frequency of exercise was also lower off-treatment than prediagnosis in breast cancer patients.[@b77-ott-9-2153] Therefore, exercise intervention should be prescribed to breast cancer survivors, encouraging them to continue their established exercise habits or adopt a right type of exercise.

Conclusion
==========

Though with some limitations, there are evidences that exercise was associated with beneficial outcomes in breast cancer survivors. Based on the results from 33 studies, exercise improved the quality of life and alleviated the symptoms of depression and anxiety in breast cancer survivors. There were also benefits on muscle strength and body composition. Besides, exercise intervention was associated with reduced serum concentration of insulin, IGF-II, and IGFBP-1. Therefore, on the basis of our current evidences, exercise should be recommended to breast cancer survivors.
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![Flow diagram of study selection.\
**Abbreviation:** RCT, randomized controlled trial.](ott-9-2153Fig1){#f1-ott-9-2153}

![The association between exercise intervention and quality of life in breast cancer survivors.\
**Notes:** (**A**) SF-36 mental health, (**B**) SF-36 general health, (**C**) FACT emotion well-being, and (**D**) FACT social well-being.\
**Abbreviations:** CI, confidence interval; FACT, Functional Assessment of Cancer Therapy; SD, standard deviation; SF-36, short form 36 questionnaire; *df*, degree of freedom.](ott-9-2153Fig2){#f2-ott-9-2153}

![The association between exercise intervention and depression and anxiety in breast cancer survivors.\
**Notes:** (**A**) Depression and (**B**) anxiety.\
**Abbreviations:** CI, confidence interval; SD, standard deviation; *df*, degree of freedom.](ott-9-2153Fig3){#f3-ott-9-2153}

![The association between exercise intervention and body mass index in breast cancer survivors.\
**Abbreviations:** CI, confidence interval; SD, standard deviation; *df*, degree of freedom.](ott-9-2153Fig4){#f4-ott-9-2153}

![The association between exercise intervention and muscle strength in breast cancer survivors.\
**Abbreviations:** CI, confidence interval; SD, standard deviation; *df*, degree of freedom.](ott-9-2153Fig5){#f5-ott-9-2153}

![The association between exercise intervention and fatigue in breast cancer survivors.\
**Notes:** (**A**) Overall effect and (**B**) subgroup analysis based on the type of exercise intervention.\
**Abbreviations:** CI, confidence interval; FACIT, Functional Assessment of Chronic Illness Therapy; SD, standard deviation; *df*, degree of freedom.](ott-9-2153Fig6){#f6-ott-9-2153}

![The association between exercise intervention and insulin and IGFBP-1 in breast cancer survivors.\
**Notes:** (**A**) Insulin and (**B**) IGFBP-1.\
**Abbreviations:** CI, confidence interval; IFGBP-1, insulin-like growth factor binding protein-1; SD, standard deviation; *df*, degree of freedom.](ott-9-2153Fig7){#f7-ott-9-2153}

###### 

Characteristics of 33 studies included in this meta-analysis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Year   Study   Author                       Mean age (SD)\                     The exercise type of intervention/control                                                              Number of subjects in intervention/control groups   Timing             Intensity                                                                           Frequency                                                            Duration                Outcomes
                                              Intervention/control                                                                                                                                                                                                                                                                                                                                                                              
  ------ ------- ---------------------------- ---------------------------------- ------------------------------------------------------------------------------------------------------ --------------------------------------------------- ------------------ ----------------------------------------------------------------------------------- -------------------------------------------------------------------- ----------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------
  2006   26      Basen-Engquist et al         55.7 (11.1)/54.4 (11.7)            Lifestyle program/standard care                                                                        35/25                                               Posttreatment      Moderate                                                                            NR                                                                   6 months                Physical performance, QoL

  2007   27      Battaglini                   56.6 (16)/57.5 (23)                Cardiovascular, resistance, flexibility/control group                                                  10/10                                               During treatment   Low-moderate: 40%--60% of predicted maximum exercise capacity                       2 times/week, ≤60 minutes                                            21 weeks                Body composition, muscle strength

  2014   28      Bower et al                  54 (5.4)                           Iyengar yoga/health education                                                                          16/15                                               Posttreatment      NR                                                                                  NR                                                                   12 weeks                Inflammation-related gene expression, circulating markers of proinflammatory cytokine, salivary cortisol

  2011   29      Cantarero-Villanueva et al   48 (9)/49 (9)                      Aerobic, resistance, neck--shoulder mobility, self-massage/usual care                                  38/40                                               Posttreatment      Aerobic: ACSM recommendations; resistance; 75% maximum load and increase            3 times/week; 90 minutes                                             8 weeks                 Fatigue, cortisol, IgA salivary levels, α-amylase activity, cervical--shoulder range of motion

  2007   30      Courneya et al               49.5/49/49                         Aerobic/resistance/usual care                                                                          82/78/82                                            During treatment   AET: 60%--80% of VO2 max; RET: 60%--70% of their estimated one repetition maximum   3 times/week                                                         Mean 17 (9--24) weeks   QoL, physical fitness, body composition, psychosocial functioning, fatigue

  2007   31      Daley et al                  51.6 (8.8)/50.6 (8.7)/51.1 (8.6)   Aerobic exercise/exercise--placebo/usual care                                                          34/46/38                                            Posttreatment      Moderate-intensity (65%--85% of age-adjusted HR maximum and RPE of 12--13)          3 times/week, 50 minutes                                             8 weeks                 QoL, depression, fatigue exercise behavior, aerobic fitness

  2006   32      Drouin et al                 49.4 (7.0)/51.9 (10)               Walking/placebo stretching                                                                             8/13                                                During treatment   50%--70% of measured maximum HRs                                                    3--5 times/week, 20--45 minutes                                      7 weeks                 Erythrocyte measures: RBC, HCT, HB, peak VO2

  2009   33      Irwin et al                  56.5 (9.5)/55.1 (7.7)              Walking/usual care                                                                                     37/38                                               Posttreatment      Moderate (60%--80% of predicted maximal HR)                                         3 times (supervised)\                                                6 months                Body composition, physical activity levels
                                                                                                                                                                                                                                                                                                                                                   +2 times (own)/week, 150 minutes                                                             

  2009   34      Irwin et al                  56.5 (9.5)/55.1 (7.7)              Walking/usual care                                                                                     37/38                                               Posttreatment      Moderate (60%--80% of predicted maximal HR)                                         3 times (supervised)\                                                6 months                Insulin, IGF-1, IGFBP-3
                                                                                                                                                                                                                                                                                                                                                   +2 times (own)/week, 150 minutes                                                             

  2011   35      Janelsins et al              54.33 (10.64)/52.7 (6.67)          Tai Chi Chuan/no exercise control                                                                      9/10                                                Posttreatment      Moderate                                                                            3 times/week, 60 minutes                                             12 weeks                Insulin, insulin-related molecules and cytokines, body composition

  2008   36      Milne et al                  55.2 (8.4)/55.1 (8.0)              Aerobic, resistance, stretching: immediate/delayed exercise group                                      29/29                                               Posttreatment      NR                                                                                  3 times/week                                                         12 weeks                QoL, fatigue, social physical anxiety, aerobic fitness

  2007   37      Mutrieet et al               51.3 (10.3)/51.8 (8.7)             Group exercise program: aerobic, resistance/usual care                                                 101/102                                             During treatment   Moderate (50%--75% of age adjusted maximum HR)                                      3 times/week, 45 minutes                                             12 weeks                QoL, depression, physical activity, shoulder mobility

  2007   38      Nikander et al               52.5 (6.4)/51.3 (7.3)              Aerobic exercise/daily activity                                                                        14/14                                               Posttreatment      Vigorous                                                                            3 times/week                                                         12 weeks                Feasibility, efficacy, physical performance

  2009   39      Rao et al                    NR                                 Yoga/brief supportive therapy                                                                          45/53                                               Before treatment   NR                                                                                  Daily/60 minutes                                                                             QoL

  2013   40      Rogers et al                 58.0 (6.1)/53.7 (13.9)             Aerobic, resistance/usual care                                                                         15/13                                               Posttreatment      Moderate                                                                            150 minutes weekly aerobic, 2 sessions/week resistance               3 months                Inflammatory-related serum markers, cardiorespiratory fitness, muscle strength, body composition, fatigue, strength, body composition, fatigue, sleep

  2009   41      Rogers et al                 52 (15)/54 (8)                     Walking/usual care                                                                                     21/20                                               Posttreatment      Moderate                                                                            150 minutes/week                                                     12 weeks                Feasibility, healthy outcome: aerobic fitness, muscle strength, body composition, QoL, sleep

  2009   42      Vadiraja et al               NR                                 Yoga/brief supportive therapy                                                                          45/53                                               Before treatment   NR                                                                                  Daily/60 minutes                                                     NR                      QoL

  2009   42      Vadiraja et al               NR                                 Yoga/brief supportive therapy                                                                          45/53                                               Before treatment   NR                                                                                  Daily/60 minutes                                                     NR                      The total caloric intake, fatigue, body composition, aerobic fitness

  2008   43      Battaglini                   57.5 (23)/56.6 (16)                Cardiovascular, stretching, resistance/control group                                                   10/10                                               During treatment   40%--60% of predicted maximum exercise capacity                                     2 times/week, ≤60 minutes                                            6 months                Peak oxygen consumption, QoL, fatigue, self-esteem, happiness, body composition

  2003   44      Courneya et al               59 (5)/58 (6)                      Cycle ergometers/no train                                                                              24/28                                               Posttreatment      70%--75% of maximal oxygen consumption in untrained subjects                        3 times/week, 15--35 minutes                                         15 weeks                QoL, fatigue, ROM of shoulder, pain

  2008   45      Hwang et al                  46.3 (7.5)/46.3 (9.5)              Stretching, aerobic exercise/self-shoulder stretching                                                  17/23                                               During treatment   50%--70% of the age-adjusted HR maximum                                             3 times/week, 50 minutes                                             5 weeks                 QoL, shoulder (ROM), body image

  2005   46      Sandel et al                 59.7 (9.8)/59.5 (13.3)             Dance and movement program/a waitlist control group                                                    19/19                                               Posttreatment      NR                                                                                  2 times/weeks for 6 weeks, 1 time/week for 6 weeks, 50--60 minutes   12 weeks                QoL, fatigue, distressed mood, spiritual well-being

  2007   47      Moadel et al                 55.11 (10.07)/54.23 (9.81)         Yoga/waitlist control group                                                                            84/44                                               Posttreatment      NR                                                                                  1.5-hour weekly classes                                              12 weeks                Fasting insulin, glucose, insulin resistance, IGFs, IGFBPs

  2003   48      Fairey et al                 59 (5)/58 (6)                      Cycle ergometers/control group                                                                         25/28                                               Posttreatment      (70%--75%) of peak oxygen consumption                                               3 times/week, 15--35 minutes                                         15 weeks                Body composition, insulin, glucose, IGF axis variables

  2005   49      Schmitz et al                53.3 (8.7)/52.8 (7.6)              Weight training: immediate/delayed group trained                                                       42/43                                               Posttreatment      Upper body: symptoms allowed; lower body: the most weight lift                      2 times/week, 60 minutes                                             12/6 months             Vigor, depression, sleep, stress, physical performance

  2012   50      Bower et al                  54.4 (5.7)/53.3 (4.9)              Lyengar yoga/health education                                                                          16/15                                                                                                                                                                                                                                                   

  2009   51      Cadmus et al                 54.5 (8.2)/54 (10.9)               Home-based exercise program: phone guide/usual care                                                    25/25                                               During treatment   Moderate-vigorous: 60%--80% of predicted maximal HR                                 5 times/week, 30 minutes                                             6 months                Happiness, depression, anxiety, stress, self-esteem, QoL

  2009   51      Cadmus et al                 56.5 (9.5)/55.1 (7.7)              Supervised exercise intervention/usual care                                                            37/37                                               Posttreatment      Moderate-vigorous: 60%--80% of predicted maximal HR                                 5 times/week, 30 minutes                                             6 months                Happiness, depression, anxiety, stress, self-esteem, QoL

  2009   52      Danhauer et al               54.3 (9.6)/57.2 (10.2)             Yoga class group/waitlist group                                                                        13/14                                               Posttreatment      NR                                                                                  1 times/week, 75 minutes                                             10 weeks                Feasibility, aerobic fitness, muscle strength, body composition, QoL, fatigue, sleep

  2012   53      Hayes et al                  51.2 (8.8)/52.2 (8.6)/53.9 (7.7)   Face-to-face/telephone exercise: aerobic strength intervention/usual care                              67/67/60                                            Posttreatment      Individually tailored                                                               4 times/week, 45 minutes                                             8 months                QoL, body function, fatigue, lymphedema, BMI, menopausal symptoms, anxiety, depression, pain

  2012   54      Littman et al                60.6 (7.1)/58.2 (8.8)              Facility-based and home-based Viniyoga intervention/waitlist control group                             27/27                                               Posttreatment      NR                                                                                  5 times/week, ≥75 minutes                                            6 months                QoL, fatigue, body composition

  2004   55      Mustian et al                52(9)                              Tai Chi Chuan/psychosocial support                                                                     11/10                                               Posttreatment      Moderate                                                                            3 times/week, 60 minutes                                             12 weeks                QoL, self-esteem

  2006   56      Ohira et al                  53.3 (8.7)/52.8 (7.6)              Weight training/control group                                                                          43/43 (39/40)                                       Posttreatment      NR                                                                                  2 times/week                                                         6 months                QoL, depression, body composition, upper and lower body strength

  2012   57      Sprod et al                  54.33 (3.55)/52.7 (2.11)           Tai Chi Chuan exercise/standard support therapy                                                        9/10                                                Posttreatment      NR                                                                                  3 times/week, 60 minutes                                             12 weeks                IL-6, IL-8, IGF-I, glucose, insulin, cortisol, IGFBP-1, IGFBP-3, QoL

  2012   58      Saarto et al                 52.3/52.4                          Step aerobics class and circuit training class (supervised), endurance training (home)/control group   263/237                                             Posttreatment      86%--92% of maximal HR, 76%--85% of maximal VO2                                     3--4 times/week: 1 supervised +2/3 home, 60 minutes                  12 months               QoL, fatigue, physical fitness, physical activity
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** ACSM, American college of sports medicine; AET, aerobic exercise training; BMI, body mass index; HB, hemoglobin; HCT, hematocrit; HR, heart rate; IFGBP, insulin-like growth factor binding protein; IGF, insulin-like growth factor; IL, interleukin; NR, not reported; QoL, quality of life; RBC, red blood cell; RET, resistance exercise training; VO2 peak, peak oxygen consumption; IgA, immunoglobulin A; SD, standard deviation; ROM, range of motion; RPE, rating of perceived exertion.

###### 

Methodological quality assessment of 33 randomized controlled trials

  Study                                               Randomization   Conceal allocation   Similarity of baseline   Specified eligibility criteria   Blinding of outcome assessor   Point estimates and measures of reliability of primary outcome   Intention-to-treat analysis
  --------------------------------------------------- --------------- -------------------- ------------------------ -------------------------------- ------------------------------ ---------------------------------------------------------------- -----------------------------
  Basen-Engquist et al, 2006[@b26-ott-9-2153]         \+              −                    \+                       \+                               \+                             \+                                                               −
  Battaglini, 2007[@b27-ott-9-2153]                   \+              −                    −                        \+                               −                              \+                                                               −
  Bower et al, 2014[@b28-ott-9-2153]                  \+              −                    \+                       \+                               −                              \+                                                               −
  Cantarero-Villanueva et al, 2011[@b29-ott-9-2153]   \+              \+                   \+                       \+                               \+                             \+                                                               \+
  Courneya et al, 2007[@b30-ott-9-2153]               \+              \+                   \+                       \+                               −                              \+                                                               −
  Daley et al, 2007[@b31-ott-9-2153]                  \+              \+                   \+                       \+                               −                              \+                                                               \+
  Drouin et al, 2006[@b32-ott-9-2153]                 \+              −                    \+                       \+                               −                              \+                                                               −
  Irwin et al, 2009[@b33-ott-9-2153]                  \+              −                    \+                       \+                               \+                             \+                                                               \+
  Irwin et al, 2009[@b34-ott-9-2153]                  \+              −                    \+                       \+                               \+                             \+                                                               \+
  Janelsins et al, 2011[@b35-ott-9-2153]              \+              \+                   \+                       \+                               −                              \+                                                               −
  Milne et al, 2008[@b36-ott-9-2153]                  \+              \+                   \+                       \+                               −                              \+                                                               \+
  Mutrieet et al, 2007[@b37-ott-9-2153]               \+              \+                   \+                       \+                               \+                             \+                                                               −
  Nikander et al, 2007[@b38-ott-9-2153]               \+              −                    \+                       \+                               −                              \+                                                               \+
  Rao et al, 2009[@b39-ott-9-2153]                    \+              −                    \+                       \+                               −                              \+                                                               \+
  Rogers et al, 2013[@b40-ott-9-2153]                 \+              −                    \+                       \+                               −                              \+                                                               \+
  Rogers et al, 2009[@b41-ott-9-2153]                 \+              \+                   \+                       \+                               −                              \+                                                               −
  Vadiraja et al, 2009[@b42-ott-9-2153]               \+              \+                   \+                       \+                               \+                             \+                                                               \+
  Battaglini, 2008[@b43-ott-9-2153]                   \+              −                    \+                       \+                               −                              \+                                                               −
  Courneya et al, 2003[@b44-ott-9-2153]               \+              \+                   \+                       \+                               \+                             \+                                                               \+
  Hwang et al, 2008[@b45-ott-9-2153]                  \+              −                    \+                       \+                               −                              \+                                                               −
  Sandel et al, 2005[@b46-ott-9-2153]                 \+              \+                   \+                       \+                               −                              \+                                                               \+
  Moadel et al, 2007[@b47-ott-9-2153]                 \+              −                    −                        \+                               −                              \+                                                               −
  Fairey et al, 2003[@b48-ott-9-2153]                 \+              \+                   \+                       \+                               \+                             \+                                                               \+
  Schmitz et al, 2005[@b49-ott-9-2153]                \+              \+                   \+                       \+                               \+                             \+                                                               −
  Bower et al, 2012[@b50-ott-9-2153]                  \+              \+                   \+                       \+                               \+                             \+                                                               \+
  Cadmus et al, 2009[@b51-ott-9-2153]                 \+              \+                   −                        \+                               −                              \+                                                               \+
  Danhauer et al, 2009[@b52-ott-9-2153]               \+              −                    \+                       \+                               −                              \+                                                               \+
  Hayes et al, 2012[@b53-ott-9-2153]                  \+              −                    \+                       \+                               −                              \+                                                               \+
  Littman et al, 2012[@b54-ott-9-2153]                \+              −                    \+                       \+                               −                              \+                                                               \+
  Mustian et al, 2004[@b55-ott-9-2153]                \+              −                    −                        \+                               −                              \+                                                               −
  Ohira et al, 2006[@b56-ott-9-2153]                  \+              −                    \+                       \+                               \+                             \+                                                               −
  Sprod et al, 2012[@b57-ott-9-2153]                  \+              −                    \+                       \+                               −                              \+                                                               \+
  Saarto et al, 2012[@b58-ott-9-2153]                 \+              −                    \+                       \+                               −                              \+                                                               \+

###### 

Meta-analysis of the effect of exercise intervention in breast cancer survivors

  Outcomes                                Study   Number of subjects in intervention/control groups   *I*^2^ (%)   *P*-value   95% CI                    Publication bias (*P*-value)
  --------------------------------------- ------- --------------------------------------------------- ------------ ----------- ------------------------- ------------------------------
  The quality of life (SF-36)             10                                                                                                             
  Mental health                           4       125/116                                             18           0.03        1.04 (0.09, 2.00)         0.917
  Role (physical)                         4       125/116                                             95           0.95        0.11 (−3.54, 3.76)        0.829
  Social function                         3       106/97                                              0            0.18        −0.36 (−0.88, 0.16)       0.289
  Vitality                                3       106/97                                              61           0.16        1.35 (−0.53, 3.23)        0.936
  Pain                                    3       106/97                                              98           0.33        2.58 (−2.65, 7.81)        0.418
  General health                          3       106/97                                              95           0.02        4.59 (0.70, 8.48)         0.113
  Role (emotion)                          3       106/97                                              13           0.6         −0.10 (−0.46, 0.26)       0.062
  FACT-G                                  6       237/200                                             87           0.08        6.02 (−0.73, 12.76)       0.482
  TACT: TOI                               2       54/57                                               96           0.23        13.04 (−8.13, 34.20)      
  FACT-G: social well-being               8       343/316                                             0            0.01        0.94 (0.19, 1.69)         0.889
  FACT-G: function well-being             8       343/316                                             83           0.07        0.37 (−0.03, 0.77)        0.589
  FACT-G: emotion well-being              8       343/316                                             2            0.0006      0.27 (0.12, 0.43)         0.889
  FACT-G: physical well-being             8       343/316                                             88           0.15        1.53 (−0.57, 3.63)        0.574
  FACT-B subscale                         5       225/238                                             15           \<0.00001   2.96 (1.87, 4.04)         0.906
  FACT-B                                  6       241/230                                             85           0.08        0.46 (−0.05, 0.97)        0.235
  Psychological outcomes                                                                                                                                 
   The Rosenberg Self-Esteem Scale        3       185/192                                             0            0.02        1.02 (0.18, 2.22)         
   The 2-item Fordyce Happiness Measure   2       87/90                                               0            0.66        1.34 (−4.64, 7.32)        
   Depression                             6       378/373                                             2            0.001       −2.08 (−3.36, −0.80)      0.236
   Anxiety                                5       341/361                                             0            \<0.0001    −3.17 (−4.76, −1.58)      0.200
   Positive and negative affect scale     3                                                                                                              
   PANAS negative                         3       142/150                                             76           0.02        −5.31 (−9.92, −0.71)      
   PANAS positive                         3       142/150                                             0            \<0.0001    4.46 (2.48, 6.44)         
   FACIT-Spiritual                        2       97/58                                               0            0.02        4.04 (0.76, 7.13)         
   The Perceived Stress Scale             2       78/77                                               0            0.08        −1.94 (−4.11, 0.22)       
  Sleep dysfunction                                                                                                                                      
   The Pittsburgh Sleep Quality Index     4       64/62                                               0            0.58        0.32 (−0.82, 1.46)        0.082
  Body composition                                                                                                                                       
   Body mass index                        9       270/283                                             0            \<0.0001    −0.78 (−1.09, −0.47)      0.599
   Lean body mass/lean mass               4       246/252                                             57           0.04        1.17 (0.08, 2,25)         0.140
   Body fat %                             5       267/272                                             57           0.02        −1.84 (−3.33, −0.35)      0.376
   Fat mass                               2       169/174                                             0            0.05        −2.44 (−4.83, −0.04)      0.212
   Waist-to-hip ratio                     2       36/33                                               21           0.19        −0.02 (−0.04, 0.01)       
   Waist circumference                    3       103/105                                             0            0.71        0.17 (−0.70, 1.03)        
   Hip circumference                      2       64/65                                               0            0.94        −0.16 (−4.27, 3.94)       
  Physical performance and function                                                                                                                      
   Fatigue                                10      841/800                                             83           0.69        0.30 (−1.16, 1.75)        0.387
   FACT-Fatigue subscale                  3       120/134                                             46           0.17        2.75 (−1.22, 6.71)        
   Fatigue Symptom Inventory              2       31/28                                               68           0.04        −0.85 (−1.68, −0.02)      
   FACIT-Fatigue                          4       469/410                                             0            0.96        0.04 (−1.2, 1.27)         
   Muscle strength                        5       235/236                                             48           0.0009      4.27 (1.76, 6.78)         0.272
   VO2 peak, mL/kg/min                    2       185/192                                             52           0.21        0.68 (−0.38, 1.75)        
   VO2 peak, mL/min                       2       185/192                                             46           0.19        0.06 (−0.03, 0.14)        
  Physiological markers                                                                                                                                  
   IL-6                                   4       46/45                                               70           0.36        1.01 (−1.14, 3.15)        
   IL-6 change                            4       46/45                                               69           0.02        1.46 (0.27, 2.65)         0.046
   IL-8                                   2       21/20                                               76           0.07        1.38 (−0.09, 2.86)        
   Glucose                                3       71/77                                               0            0.35        0.27 (−0.29, 0.82)        
   Glucose change                         3       71/77                                               99           \<0.00001   1.73 (1.36, 2.11)         0.687
   Insulin                                5       117/126                                             95           0.05        −6.79 (−13.64, 0.06)      
   Insulin change                         5       117/126                                             97           0.04        −4.98 (−9.26, −0.33)      0.353
   IGF-1                                  5       119/126                                             99           0.47        7.46 (−12.94, 27.87)      
   IGF-1 change                           5       119/126                                             99           0.53        6.5 (−13.88, 26.89)       0.957
   IGF-II                                 2       64/68                                               88           0.94        4.36 (−110.03, 118.75)    
   IGF-II change                          2       64/68                                               0            \<0.0001    −54.21 (−61.41, −47.00)   
   IGFBP-1                                4       82/88                                               46           \<0.0001    −3.16 (−4.40, −1.91)      
   IGFBP-1 change                         4       82/88                                               0            \<0.0001    −2.93 (−3.93, −1.93)      0.639
   IGFBP-3                                5       119/126                                             93           0.9         −0.2 (−3.24, 2.48)        0.830
   IGFBP-3 change                         5       119/126                                             86           0.55        0.49 (−1.11, 2.08)        

**Abbreviations:** FACT-B, Functional Assessment of Cancer Therapy--Breast Questionnaire; FACT-G, Functional Assessment of Cancer Therapy-General; FACIT--Spiritual, Functional Assessment of Chronic Illness Therapy--Spiritual well-being scale; IGF-I, insulin-like growth factor-I; IGF-II, insulin-like growth factor-II; IGFBP-1, insulin-like growth factor binding protein-1; IGFBP-3, insulin-like growth factor binding protein-3; IL, interleukin; PANAS, Positive and Negative Affect Schedule; SF-36, short form 36 questionnaire; VO2 peak, peak oxygen consumption; CI, confidence interval; TOI, Trial Outcome Index; FACIT-Fatigue, Functional Assessment of Chronic Illness Therapy--Fatigue Scale.
